Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849264 | 0.90 | — | — | |
| SCHEMBL20666526 | 0.81 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL29332959 | 0.77 | ALDH1A1 (0.31) | ALDH1A1MEN1POLBKMT2AL3MBTL1 | |
| SCHEMBL12120617 | 0.76 | RXRA (0.35) | ALDH1A1POLB | |
| SCHEMBL21653572 | 0.74 | — | — | |
| SCHEMBL20411878 | 0.74 | UHRF1 (0.37) | ALDH1A1POLBKMT2A | |
| SCHEMBL21161714 | 0.73 | ALPL (0.39) | ALDH1A1L3MBTL1 | |
| SCHEMBL19441910 | 0.73 | ESR1 (0.32) | ALDH1A1MEN1POLBKMT2AL3MBTL1 | |
| SCHEMBL1890998 | 0.73 | HSP90AA1 (0.37) | ALDH1A1MEN1POLBKMT2AL3MBTL1 | |
| SCHEMBL24554448 | 0.73 | HSP90AA1 (0.37) | ALDH1A1MEN1POLBKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-04 | — | — | US | disclosed |
| US-11241450-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | TUFTS UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210069226-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | TUFTS UNIVERSITY (US) | 2021-03-11 | — | — | US | disclosed |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138480-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885MEN1 1366/4885POLB 165/4885 |
| US-20210069226-A1 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF | UMPS, UPP1, UGDH | ALDH1A1 1514/4885MEN1 4056/4885POLB 553/4885 |
| US-11241450-B2 | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof | UMPS, UPP1, UGDH | ALDH1A1 1514/4885MEN1 4056/4885POLB 553/4885 |
| US-20210038611-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885MEN1 1366/4885POLB 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.